Currently, Medicare coverage for anti-obesity medications is limited to indications for diabetes and cardiovascular disease. Policymakers, however, have proposed expanding this to authorize broader Medicare coverage for these medications. On October 8, the Congressional Budget Office (CBO) released a report estimating the budgetary effects of an illustrative policy that would allow Medicare coverage for anti-obesity medications (AOM) beginning January 2026. The CBO’s analysis projects that initial savings from beneficiaries’ improved health would be modest, estimated at less than $50 million in 2026, with potential savings growing to $1 billion by 2034. Read the report.
Last Updated on November 22, 2024 by Aimed Alliance
